Retrieve Medical (RMHI) 10-Q 19 Dec 22 2020 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jun. 30, 2020	Dec. 16, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--09-30
Entity File Number	005-87668
Entity Registrant Name	PEAK PHARMACEUTICALS, INC.
Entity Central Index Key	0001452804
Entity Incorporation, State or Country Code	NV
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		78,363,567

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Current Assets
Cash	$ 438	$ 527
Total current assets	438	527
Total Assets	438	527
Current liabilities:
Accounts payable (including $87,237 and $87,237 due to related parties)	160,540	157,117
Accrued liabilities	22,590	15,495
Convertible notes payable	20,000	20,000
Notes payable	43,000	43,000
Total current liabilities	246,130	235,612
Total Liabilities	246,130	235,612
Stockholders' Deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding	7,836	7,836
Additional paid in capital	4,855,566	4,855,566
Accumulated deficit	(5,109,094)	(5,098,487)
Total Stockholders' Deficit	(245,692)	(235,085)
Total Liabilities and Stockholders' Deficit	$ 438	$ 527

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Statement of Financial Position [Abstract]
Accounts Payable, Related Parties, Current	$ 87,237	$ 87,237
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	78,363,567	78,363,567
Common stock, shares outstanding	78,363,567	78,363,567

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating expenses:
General and administrative (including fees paid to related party of $0 and $0, and $0 and $1,253, for the three and nine months ended June 30, 2020 and 2019, respectively)	$ 1,204	$ 1,483	$ 3,513	$ 4,209
Total operating expenses	1,204	1,483	3,513	4,209
Operating loss	(1,204)	(1,483)	(3,513)	(4,209)
Other expenses:
Interest expense	(2,356)	(2,176)	(7,094)	(5,946)
Total other expenses	(2,356)	(2,176)	(7,094)	(5,946)
Net loss	$ (3,560)	$ (3,659)	$ (10,607)	$ (10,155)
Per share information:
Weighted average shares outstanding - basic and diluted	78,363,567	78,363,567	78,363,567	78,363,567
Net loss per share - basic and diluted	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Related Party, General and Administrative Expenses	$ 0	$ 0	$ 0	$ 1,253

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Sep. 30, 2018	$ 7,836	$ 4,855,566	$ (5,084,494)	$ (221,092)
Beginning Balance, Shares at Sep. 30, 2018	78,363,567
Net income			(2,859)	(2,859)
Ending Balance, Amount at Dec. 31, 2018	$ 7,836	4,855,566	(5,087,353)	(223,951)
Ending Balance, Shares at Dec. 31, 2018	78,363,567
Beginning Balance, Amount at Sep. 30, 2018	$ 7,836	4,855,566	(5,084,494)	(221,092)
Beginning Balance, Shares at Sep. 30, 2018	78,363,567
Net income				(10,155)
Ending Balance, Amount at Jun. 30, 2019	$ 7,836	4,855,566	(5,094,649)	(231,247)
Ending Balance, Shares at Jun. 30, 2019	78,363,567
Beginning Balance, Amount at Dec. 31, 2018	$ 7,836	4,855,566	(5,087,353)	(223,951)
Beginning Balance, Shares at Dec. 31, 2018	78,363,567
Net income			(3,637)	(3,637)
Ending Balance, Amount at Mar. 31, 2019	$ 7,836	4,855,566	(5,090,990)	(227,588)
Ending Balance, Shares at Mar. 31, 2019	78,363,567
Net income			(3,659)	(3,659)
Ending Balance, Amount at Jun. 30, 2019	$ 7,836	4,855,566	(5,094,649)	(231,247)
Ending Balance, Shares at Jun. 30, 2019	78,363,567
Beginning Balance, Amount at Sep. 30, 2019	$ 7,836	4,855,566	(5,098,487)	(235,085)
Beginning Balance, Shares at Sep. 30, 2019	78,363,567
Net income			(3,520)	(3,520)
Ending Balance, Amount at Dec. 31, 2019	$ 7,836	4,855,566	(5,102,007)	(238,605)
Ending Balance, Shares at Dec. 31, 2019	78,363,567
Beginning Balance, Amount at Sep. 30, 2019	$ 7,836	4,855,566	(5,098,487)	(235,085)
Beginning Balance, Shares at Sep. 30, 2019	78,363,567
Net income				(10,607)
Ending Balance, Amount at Jun. 30, 2020	$ 7,836	4,855,566	(5,109,094)	(245,692)
Ending Balance, Shares at Jun. 30, 2020	78,363,567
Beginning Balance, Amount at Dec. 31, 2019	$ 7,836	4,855,566	(5,102,007)	(238,605)
Beginning Balance, Shares at Dec. 31, 2019	78,363,567
Net income			(3,527)	(3,527)
Ending Balance, Amount at Mar. 31, 2020	$ 7,836	4,855,566	(5,105,534)	(242,132)
Ending Balance, Shares at Mar. 31, 2020	78,363,567
Net income			(3,560)	(3,560)
Ending Balance, Amount at Jun. 30, 2020	$ 7,836	$ 4,855,566	$ (5,109,094)	$ (245,692)
Ending Balance, Shares at Jun. 30, 2020	78,363,567

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended				9 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ (3,560)	$ (3,520)	$ (3,659)	$ (2,859)	$ (10,607)	$ (10,155)
Change in operating assets and liabilities:
Accounts payable					3,423	(2,517)
Accounts payable - related parties						5,013
Accrued expenses					7,095	5,947
Net cash used in operating activities					(89)	(1,712)
Net change in cash					(89)	(1,712)
Cash, beginning of period		$ 527		$ 2,270	527	2,270
Cash, end of period	$ 438		$ 558		438	558
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jun. 30, 2020
Nature Of Operations Basis Of Presentation And Summary Of Significant Accounting Policies
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was incorporated in Nevada on December 18, 2007. After a number of name changes, we again, changed our name to Peak Pharmaceuticals, Inc. on December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. On October 1, 2015, we discontinued certain operations of the Company. The Company is currently a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act). Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its wholly-owned subsidiary, Peak BioPharma Corp. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2019. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period. Basis of Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt. Loss Per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share As of June 30, 2020 and September 30, 2019, the Company had two convertible notes with principal and accrued interest balances totaling $28,610 and $26,357, respectively. The note holders are entitled, at their option, to convert all or a part of their options at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 2,432,789 and 871,979 shares as of June 30, 2020 and 2019 , respectively, are not included in the calculation of diluted EPS as their effect would be anti-dilutive. As of June 30, 2020 and September 30, 2019, the Company had 3,291,000 in stock options outstanding which are exercisable at the holders’ option, with an exercise price of $0.0067, which are not included in the calculation of diluted EPS as their effect would be anti-dilutive. Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In February 2016, the FASB issued ASU No. 2016-02, Leases,

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Jun. 30, 2020
Going Concern And Managements Liquidity Plans
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of June 30, 2020, the Company had an accumulated deficit of $5,109,094 and a working capital deficiency of $245,692. During the nine months ended June 30, 2020, the Company incurred a net loss of $10,607 and used cash in operating activities of $89. As of June 30, 2020, the Company had cash of $438. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations and meet its payment obligations. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Jun. 30, 2020
Related Party Transactions
RELATED PARTY TRANSACTIONS	NOTE 3 – RELATED PARTY TRANSACTIONS Parties, which can be corporations or individuals, are considered to be related if they have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence. Accounts payable – related parties are amounts payable to current and former officers and directors for services provided to the Company totaling $87,237 and $87,237, As of June 30, 2020 and September 30, 2019, respectively. These amounts include accounts payable to an entity controlled by our sole officer and director for financial services such entity is incurring on behalf of the Company totaling $12,360 and $12,360 as of June 30, 2020 and September 30, 2019, respectively. Total expense incurred related to this entity was $0 and $0 for the three months ended June 30, 2020 and 2019, respectively, and $0 and $1,253 for the nine months ended June 30, 2020 and 2019, respectively, with no other related party expenses incurred.

CONVERTIBLE NOTES PAYABLE AND N

CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE	9 Months Ended
	Jun. 30, 2020
Convertible Notes Payable And Notes Payable
CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE	NOTE 4 – CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE Convertible Notes Payable Loan with Trius Holdings Limited On March 17, 2017, the Company entered into an agreement with Trius Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. Trius is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019. As of June 30, 2020 and September 30, 2019, the total accrued interest owing under this note was $4,327 and $3,201, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%. Loan with Individual On March 30, 2017, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, the individual acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019. As of June 30, 2020 and September 30, 2019, the total accrued interest owing under this note was $4,282 and $3,156 respectively. Subsequent to the nine months ended June 30, 2020, on December 3, 2021, the Company repaid this loan and accrued interest in full. Notes Payable Loan with Mediapark Investments Limited On January 10, 2018, the Company entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018 and is unsecured. As of July 9, 2018, the loan was extended to July 10, 2019. As of June 30, 2020 and September 30, 2019, the total accrued interest owing under this note was $7,494 and $4,904, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%. Loan with Individual On April 2, 2018, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a promissory note in the amount of $20,000. The note is unsecured, is due and payable in full on October 2, 2018, and it accrues interest at a rate of 12% per annum. As of the June 30, 2020 and September 30, 2019, the total accrued interest owing under this note was $6,127 and $3,875, respectively. Subsequent to the nine months ended June 30, 2020, on December 3, 2021, the Company repaid this loan and accrued interest in full.

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Jun. 30, 2020
Stock Options
STOCK OPTIONS	NOTE 5 – OPTIONS No stock options were granted during the nine months ended June 30, 2020 and 2019. The following is a summary of outstanding stock options issued to employees and directors As of June 30, 2020 and September 30, 2019: Number Exercise Price per Average Outstanding June 30, 2020 and September 30, 2019 2,916,000 $ 0.0067 3.70 Exercisable, June 30, 2020 and September 30, 2019 2,916,000 $ 0.0067 3.70 The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of June 30, 2020 and September 30, 2019: Number Exercise Price per Average Outstanding June 30, 2020 and September 30, 2019 375,000 $ 0.0067 3.29 Exercisable, June 30, 2020 and September 30, 2019 375,000 $ 0.0067 3.29 There was no equity-based compensation for the nine months ended June 30, 2020 and 2019.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jun. 30, 2020
Subsequent Events
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS Issuance of Loans Payable During the year ended September 30, 2021, the Company received an aggregate of $275,000 related to the issuance of 14 notes payable to various noteholders, including an aggregate of $35,000 as a result of two notes payable issued to the Company’s Chief Executive Officer, a related party. The notes are unsecured, bear interest at 1.5% per annum, and mature on September 30, 2021. To date, the Company has made principal and accrued interest payment of $65,000 and $14,191, respectively. As of the date of this report, the original due date of such notes has not been extended and are in default.

NATURE OF OPERATIONS, BASIS O_2

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jun. 30, 2020
Disclosure Nature Of Operations Basis Of Presentation And Summary Of Significant Accounting Policies Policies Abstract
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2019. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.
Basis of Consolidation	Basis of Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.
Loss Per Share	Loss Per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share As of June 30, 2020 and September 30, 2019, the Company had two convertible notes with principal and accrued interest balances totaling $28,610 and $26,357, respectively. The note holders are entitled, at their option, to convert all or a part of their options at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 2,432,789 and 871,979 shares as of June 30, 2020 and 2019 , respectively, are not included in the calculation of diluted EPS as their effect would be anti-dilutive. As of June 30, 2020 and September 30, 2019, the Company had 3,291,000 in stock options outstanding which are exercisable at the holders’ option, with an exercise price of $0.0067, which are not included in the calculation of diluted EPS as their effect would be anti-dilutive.
Recent Pronouncements	Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In February 2016, the FASB issued ASU No. 2016-02, Leases,

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Jun. 30, 2020
Employee
Schedule of share-based compensation, stock options, activity	The following is a summary of outstanding stock options issued to employees and directors As of June 30, 2020 and September 30, 2019: Number Exercise Price per Average Outstanding June 30, 2020 and September 30, 2019 2,916,000 $ 0.0067 3.70 Exercisable, June 30, 2020 and September 30, 2019 2,916,000 $ 0.0067 3.70
Non-Employee
Schedule of share-based compensation, stock options, activity	The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of June 30, 2020 and September 30, 2019: Number Exercise Price per Average Outstanding June 30, 2020 and September 30, 2019 375,000 $ 0.0067 3.29 Exercisable, June 30, 2020 and September 30, 2019 375,000 $ 0.0067 3.29

NATURE OF OPERATIONS, BASIS O_3

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure Nature Of Operations Basis Of Presentation And Summary Of Significant Accounting Policies Details Narrative Abstract
Anti-Dilutive Shares Excluded from Earning Per Share	2,432,789	871,979
Options outstanding	3,291,000
Cash and cash equivalents	$ 0

GOING CONCERN AND MANAGEMENT'_2

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019
Disclosure Going Concern And Managements Liquidity Plans Details Narrative Abstract
Accumulated deficit	$ (5,109,094)						$ (5,109,094)		$ (5,098,487)
Working captial deficiency	(245,692)						(245,692)
Net Loss	(3,560)	$ (3,527)	$ (3,520)	$ (3,659)	$ (3,637)	$ (2,859)	(10,607)	$ (10,155)
Cash used in operating activities							(89)	$ (1,712)
Cash	$ 438						$ 438		$ 527

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019
Account Payable - Related Parties	$ 87,237		$ 87,237		$ 87,237
Related Party, General and Administrative Expenses	0	$ 0	0	$ 1,253
Entity Controller By Sole Officer and Director [Member]
Account Payable - Related Parties	$ 12,360		$ 12,360		$ 12,360

CONVERTIBLE NOTES PAYABLE AND_2

CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2020	Sep. 30, 2019	Apr. 02, 2019	Jan. 10, 2019	Mar. 30, 2018	Mar. 17, 2018
Convertible notes payable	$ 20,000	$ 20,000
Notes payable	43,000	43,000
Trius Holdings Limited [Member]
Convertible notes payable						$ 10,000
Accured Interest	4,327	3,201
Individual [Member]
Convertible notes payable					$ 10,000
Accured Interest	4,282	3,156
Mediapark Investments Limited [Member]
Notes payable				$ 23,000
Accured Interest	7,494	4,904
Individual [Member]
Notes payable			$ 20,000
Accured Interest	$ 6,127	$ 3,875

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2019
Number of Options
Number of Options Outstanding, Ending	3,291,000
Employee
Number of Options
Number of Options Outstanding, Beginning	2,916,000
Number of Options Outstanding, Ending	2,916,000	2,916,000
Number of Options, Exercisable	2,916,000	2,916,000
Exercise Price per Share
Exercise Price per Share Outstanding, Beginning	$ 0.0067
Exercise Price per Share Outstanding, Ending	0.0067	$ 0.0067
Exercise Price per Share, Exercisable	$ 0.0067	$ 0.0067
Average Remaining Term (in Years)
Average Remaining Terms Outstanding, Ending	3 years 8 months 12 days	3 years 8 months 12 days
Average Remaining Terms, Exersiable	3 years 8 months 12 days	3 years 8 months 12 days
Non-Employee
Number of Options
Number of Options Outstanding, Beginning	375,000
Number of Options Outstanding, Ending	375,000	375,000
Number of Options, Exercisable	375,000	375,000
Exercise Price per Share
Exercise Price per Share Outstanding, Beginning	$ 0.0067
Exercise Price per Share Outstanding, Ending	0.0067	$ 0.0067
Exercise Price per Share, Exercisable	$ 0.0067	$ 0.0067
Average Remaining Term (in Years)
Average Remaining Terms Outstanding, Ending	3 years 3 months 14 days	3 years 3 months 14 days
Average Remaining Terms, Exersiable	3 years 3 months 14 days	3 years 3 months 14 days